Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.
about
Thyroid computed tomography imaging: pictorial review of variable pathologies.What is the Minimal Surgery for Papillary Thyroid Carcinoma?Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical ImplicationsRAS mutations in thyroid cancerBoth BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.Integrated genomic characterization of papillary thyroid carcinomaSignificance of the Extracapsular Spread of Metastatic Lymph Nodes in Papillary Thyroid Carcinoma2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerConservative management of well-differentiated thyroid cancerMalignant thyroid bed mass after total thyroidectomy.Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms.Endoscopic tumor ablation for laryngotracheal intraluminal invasion secondary to advanced thyroid cancer.A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population.Current concepts and future directions in differentiated thyroid cancer.Aggressiveness of the tall cell variant of papillary thyroid carcinoma is independent of the tumor size and patient age.Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profileThe pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma.S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging.BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Autoantibody against WD repeat domain 1 is a novel serological biomarker for screening of thyroid neoplasia.MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroMultikinase inhibitors use in differentiated thyroid carcinoma.Prediction of extrathyroidal extension using ultrasonography and computed tomography.Thyroid cancer: burden of illness and management of diseaseReproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer.The expression of twist in differentiated thyroid carcinomas.Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.Preoperative imaging modalities to predict the risk of regional nodal recurrence in well-differentiated thyroid cancersAdjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancerA detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma.A cross-specialty survey to assess the application of risk stratified surgery for differentiated thyroid cancer in the UK.Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis.Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancerUse of radioactive iodine for thyroid cancer.Geriatric thyroidology: An update.Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer.Management of thyroid carcinoma-an experience in Bangladesh.Controversies and challenges in the management of well-differentiated thyroid cancer.
P2860
Q26748491-EA08B70A-E547-4FF7-89B3-F1420F07F403Q26765080-8B0C799F-7CAC-4FFD-86E9-FD61E4DBEB10Q26765085-694DB342-4041-4129-9C39-94505C4DA17AQ27026163-06FD1B97-069A-4902-8585-DD5B20613EB5Q27851648-1EC40828-0D11-4D58-8C59-FC5D6C6E75EBQ28251986-FB11968C-D8D3-4DBF-9624-E05C8B0A2EE3Q28266858-1117C9EB-23FE-4102-9C2C-A129F8492493Q30367068-61F04750-855A-47B2-84D5-E40299719026Q30387260-EAC4E7B4-691D-4358-B217-9368A06CBBF1Q30449566-3F478514-E6DF-4F59-AE13-0C1DE9DF3889Q30571649-83EF342C-712A-4A9B-A3BE-96A4F715F0DDQ33345373-F08EA5EB-1032-4580-894B-379835F1FA29Q33427321-AFC96388-7BF6-4648-992E-B5E39D83245BQ33570297-54CCE34C-1197-4C3E-B7DC-263B98D6B137Q33648181-EE9E2B6E-9BE2-44B7-96A8-61B194FC7539Q33677589-E2106599-753F-4E5C-B40E-622809E07F55Q33685745-3782C45B-5044-4566-A5CE-B4EBCFC0CBA9Q33713817-70BA653C-0A5A-4D75-82DE-597D7E7CC8A8Q33973108-7BBC46AA-21BA-4D45-B28E-9381BBAB7275Q34027466-83C1D704-158E-44E6-A70C-9278FE855026Q34103836-2853C04B-6BD9-45A0-ADC4-E5A79A1C299AQ34502078-EAE482BC-9601-4672-A505-B685A5359873Q34615021-3A5EF709-F4D9-4638-96AC-1C40D7BB1EB3Q34660901-28A20D40-C0D8-411A-A23A-B68F24C15CE1Q34698065-C199FD20-D5C6-412B-91FA-97E83744408DQ34821078-CEE0E5E0-2FBF-4730-BF05-AB13D07E5D42Q34918474-94C141C5-C7B4-45AE-BFD6-F5C0171DEA45Q35121406-2186A2F9-8BDA-4C22-9FD1-4583D9BA8220Q35163702-F764ED2E-0321-40F4-8D49-6E448BC28A5CQ35440774-0ABC55E5-4C01-4F91-A552-8341D73D4C59Q35441834-0F62F0F3-381A-4593-95ED-237E31DD4F73Q35558293-4865ED82-1B35-41F2-BC0B-B0C24B8AFB47Q35760244-AE97EBA7-AECA-41F9-9080-9C841BA232FFQ35857918-07992E0F-06AE-4DA0-9A11-78964C54A913Q35908104-2922FC58-5BC7-4654-8147-71E2F1389D48Q35961413-AF281763-D704-42A9-8057-06B635CBDAB8Q36107776-D188CCC5-0955-43E6-BD2F-8D34EB95F3DCQ36240455-AEC8DFFE-E58D-4840-82D6-727E403817AFQ36260094-39C36FAE-FA49-4297-8A58-6C43D3CEF040Q36262288-070CB47E-93C8-4654-82E6-5F889BB2A83B
P2860
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Papillary thyroid carcinoma ma ...... onsecutively treated patients.
@ast
Papillary thyroid carcinoma ma ...... onsecutively treated patients.
@en
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades
@nl
type
label
Papillary thyroid carcinoma ma ...... onsecutively treated patients.
@ast
Papillary thyroid carcinoma ma ...... onsecutively treated patients.
@en
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades
@nl
prefLabel
Papillary thyroid carcinoma ma ...... onsecutively treated patients.
@ast
Papillary thyroid carcinoma ma ...... onsecutively treated patients.
@en
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades
@nl
P2093
P1476
Papillary thyroid carcinoma ma ...... onsecutively treated patients.
@en
P2093
Ann L Oberg
Brian P Mullan
Bryan McIver
Catherine E Dvorak
Claudia C Powell
Clive S Grant
Colum A Gorman
Eric J Bergstralh
Geoffrey B Thompson
P2888
P304
P356
10.1007/S00268-002-6612-1
P577
2002-05-21T00:00:00Z
P6179
1000896133